| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arsenic | 28 | 2025 | 272 | 4.040 |
Why?
|
| DNA Methylation | 21 | 2025 | 703 | 2.830 |
Why?
|
| Telomere | 9 | 2025 | 121 | 2.200 |
Why?
|
| Transcriptome | 7 | 2025 | 770 | 2.060 |
Why?
|
| Colorectal Neoplasms | 7 | 2024 | 1069 | 2.020 |
Why?
|
| Environmental Exposure | 20 | 2025 | 357 | 1.660 |
Why?
|
| Polymorphism, Single Nucleotide | 37 | 2025 | 2494 | 1.640 |
Why?
|
| Genome-Wide Association Study | 27 | 2025 | 1763 | 1.600 |
Why?
|
| Water Pollutants, Chemical | 13 | 2022 | 140 | 1.580 |
Why?
|
| Skin Neoplasms | 6 | 2025 | 625 | 1.550 |
Why?
|
| Gene-Environment Interaction | 4 | 2025 | 120 | 1.520 |
Why?
|
| Genome, Human | 10 | 2019 | 824 | 1.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2025 | 1351 | 1.330 |
Why?
|
| Bangladesh | 39 | 2025 | 339 | 1.290 |
Why?
|
| Arsenic Poisoning | 15 | 2023 | 104 | 1.280 |
Why?
|
| Telomere Shortening | 4 | 2021 | 25 | 1.200 |
Why?
|
| Gene Expression Profiling | 8 | 2025 | 1534 | 1.150 |
Why?
|
| Microsatellite Instability | 2 | 2024 | 64 | 1.030 |
Why?
|
| Mutation | 6 | 2024 | 4374 | 0.980 |
Why?
|
| Skin Diseases | 8 | 2019 | 176 | 0.940 |
Why?
|
| Colonic Neoplasms | 2 | 2020 | 589 | 0.930 |
Why?
|
| DNA | 5 | 2023 | 1332 | 0.880 |
Why?
|
| Breast Neoplasms | 17 | 2023 | 3147 | 0.850 |
Why?
|
| Sequence Deletion | 1 | 2025 | 213 | 0.850 |
Why?
|
| Drinking Water | 6 | 2023 | 70 | 0.830 |
Why?
|
| Carcinoma, Papillary | 2 | 2023 | 161 | 0.820 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 180 | 0.780 |
Why?
|
| Genetic Predisposition to Disease | 23 | 2024 | 2473 | 0.750 |
Why?
|
| Middle Aged | 57 | 2025 | 28363 | 0.750 |
Why?
|
| Humans | 105 | 2025 | 96127 | 0.730 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 8 | 2017 | 701 | 0.730 |
Why?
|
| Female | 69 | 2025 | 50063 | 0.660 |
Why?
|
| Thyroid Neoplasms | 2 | 2023 | 443 | 0.650 |
Why?
|
| Adult | 52 | 2025 | 28718 | 0.650 |
Why?
|
| Male | 58 | 2025 | 45870 | 0.650 |
Why?
|
| Bevacizumab | 1 | 2020 | 276 | 0.600 |
Why?
|
| Fluorouracil | 1 | 2020 | 555 | 0.590 |
Why?
|
| Aged | 29 | 2025 | 20964 | 0.580 |
Why?
|
| High-Throughput Screening Assays | 1 | 2018 | 65 | 0.530 |
Why?
|
| Aging | 4 | 2025 | 766 | 0.530 |
Why?
|
| Specimen Handling | 4 | 2019 | 109 | 0.500 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 191 | 0.490 |
Why?
|
| Telomere Homeostasis | 4 | 2021 | 30 | 0.490 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2016 | 137 | 0.480 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2024 | 1230 | 0.480 |
Why?
|
| Genotype | 14 | 2019 | 1882 | 0.470 |
Why?
|
| Blotting, Southern | 1 | 2014 | 128 | 0.440 |
Why?
|
| Longitudinal Studies | 13 | 2023 | 1175 | 0.430 |
Why?
|
| Tissue Fixation | 2 | 2012 | 40 | 0.430 |
Why?
|
| Chromosome Aberrations | 3 | 2019 | 393 | 0.430 |
Why?
|
| Formaldehyde | 2 | 2012 | 53 | 0.430 |
Why?
|
| Paraffin Embedding | 2 | 2012 | 79 | 0.430 |
Why?
|
| Air Pollutants | 3 | 2024 | 109 | 0.420 |
Why?
|
| Feces | 4 | 2020 | 360 | 0.420 |
Why?
|
| Air Pollution | 3 | 2024 | 107 | 0.420 |
Why?
|
| Quantitative Trait Loci | 4 | 2022 | 632 | 0.420 |
Why?
|
| CpG Islands | 8 | 2024 | 169 | 0.400 |
Why?
|
| Antioxidants | 3 | 2013 | 233 | 0.380 |
Why?
|
| Bacteria | 5 | 2020 | 517 | 0.380 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 647 | 0.380 |
Why?
|
| Risk Factors | 18 | 2023 | 5960 | 0.370 |
Why?
|
| Organ Specificity | 4 | 2025 | 285 | 0.370 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2020 | 590 | 0.370 |
Why?
|
| Epigenesis, Genetic | 6 | 2025 | 554 | 0.370 |
Why?
|
| Selenomethionine | 2 | 2013 | 11 | 0.360 |
Why?
|
| Case-Control Studies | 16 | 2023 | 1958 | 0.360 |
Why?
|
| Cardiovascular Diseases | 6 | 2023 | 777 | 0.350 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 272 | 0.330 |
Why?
|
| Neoplasms | 5 | 2023 | 3250 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 2642 | 0.320 |
Why?
|
| Methyltransferases | 5 | 2025 | 213 | 0.290 |
Why?
|
| Genetic Loci | 3 | 2015 | 260 | 0.290 |
Why?
|
| Reproducibility of Results | 5 | 2019 | 2883 | 0.290 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2008 | 43 | 0.290 |
Why?
|
| Precancerous Conditions | 2 | 2007 | 206 | 0.290 |
Why?
|
| Particulate Matter | 3 | 2024 | 124 | 0.290 |
Why?
|
| Colon | 1 | 2012 | 541 | 0.290 |
Why?
|
| RNA, Ribosomal, 16S | 5 | 2020 | 259 | 0.280 |
Why?
|
| Young Adult | 12 | 2023 | 7025 | 0.270 |
Why?
|
| Precision Medicine | 1 | 2012 | 451 | 0.270 |
Why?
|
| Incidence | 3 | 2022 | 1715 | 0.260 |
Why?
|
| Smoking | 4 | 2024 | 653 | 0.250 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2018 | 40 | 0.250 |
Why?
|
| Blood Pressure | 4 | 2024 | 929 | 0.250 |
Why?
|
| Arsenicals | 3 | 2023 | 49 | 0.250 |
Why?
|
| Glutathione Transferase | 2 | 2025 | 116 | 0.240 |
Why?
|
| Oxygenases | 1 | 2025 | 17 | 0.230 |
Why?
|
| Loss of Heterozygosity | 3 | 2012 | 86 | 0.230 |
Why?
|
| Body Mass Index | 4 | 2019 | 815 | 0.230 |
Why?
|
| Biomarkers, Tumor | 4 | 2018 | 1665 | 0.220 |
Why?
|
| Metals | 1 | 2025 | 102 | 0.210 |
Why?
|
| Leukocytes | 3 | 2025 | 218 | 0.210 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2012 | 426 | 0.210 |
Why?
|
| Receptors, Estrogen | 2 | 2016 | 417 | 0.210 |
Why?
|
| Vascular Stiffness | 1 | 2024 | 30 | 0.210 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2024 | 63 | 0.210 |
Why?
|
| Gene Expression Regulation | 5 | 2018 | 2059 | 0.210 |
Why?
|
| Chicago | 6 | 2024 | 1503 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2024 | 107 | 0.210 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2019 | 212 | 0.210 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2024 | 1105 | 0.200 |
Why?
|
| Microsatellite Repeats | 1 | 2024 | 151 | 0.200 |
Why?
|
| Hypertension | 2 | 2022 | 777 | 0.200 |
Why?
|
| Sex Factors | 2 | 2020 | 1133 | 0.200 |
Why?
|
| Cigarette Smoking | 1 | 2024 | 48 | 0.200 |
Why?
|
| Interleukin-17 | 1 | 2024 | 110 | 0.200 |
Why?
|
| Prevalence | 4 | 2023 | 1349 | 0.200 |
Why?
|
| Genetic Variation | 6 | 2022 | 1423 | 0.190 |
Why?
|
| Metabolome | 1 | 2023 | 63 | 0.190 |
Why?
|
| Microbiota | 2 | 2018 | 426 | 0.190 |
Why?
|
| Population Health | 1 | 2022 | 33 | 0.190 |
Why?
|
| Prospective Studies | 8 | 2023 | 4671 | 0.190 |
Why?
|
| Insurance Coverage | 1 | 2023 | 144 | 0.190 |
Why?
|
| Water Pollution, Chemical | 4 | 2012 | 21 | 0.190 |
Why?
|
| Gene Dosage | 3 | 2012 | 212 | 0.190 |
Why?
|
| Multifactorial Inheritance | 3 | 2024 | 201 | 0.180 |
Why?
|
| Cohort Studies | 8 | 2023 | 3107 | 0.180 |
Why?
|
| Liver Neoplasms | 3 | 2012 | 793 | 0.180 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2023 | 162 | 0.180 |
Why?
|
| DNA, Bacterial | 2 | 2019 | 253 | 0.180 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 1874 | 0.180 |
Why?
|
| Alleles | 4 | 2019 | 1157 | 0.180 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2022 | 66 | 0.180 |
Why?
|
| Environmental Pollutants | 2 | 2014 | 56 | 0.180 |
Why?
|
| Polymorphism, Genetic | 3 | 2015 | 829 | 0.170 |
Why?
|
| Cacodylic Acid | 3 | 2021 | 22 | 0.170 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2021 | 49 | 0.170 |
Why?
|
| Phenotype | 6 | 2019 | 2579 | 0.160 |
Why?
|
| Epigenomics | 2 | 2024 | 107 | 0.160 |
Why?
|
| Inflammation | 3 | 2024 | 1068 | 0.160 |
Why?
|
| Medicare | 1 | 2023 | 458 | 0.160 |
Why?
|
| Databases, Genetic | 2 | 2012 | 282 | 0.160 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 1999 | 36 | 0.160 |
Why?
|
| Vitamin E | 3 | 2014 | 34 | 0.160 |
Why?
|
| Blood | 1 | 2019 | 69 | 0.150 |
Why?
|
| Selenium | 3 | 2014 | 46 | 0.150 |
Why?
|
| Disease Progression | 1 | 2024 | 1568 | 0.150 |
Why?
|
| Ammonia-Lyases | 1 | 2019 | 6 | 0.150 |
Why?
|
| Glutamate Formimidoyltransferase | 1 | 2019 | 6 | 0.150 |
Why?
|
| Abdominal Pain | 1 | 2020 | 145 | 0.150 |
Why?
|
| Developing Countries | 1 | 1999 | 91 | 0.150 |
Why?
|
| Anthropometry | 1 | 2019 | 78 | 0.150 |
Why?
|
| Autophagy | 1 | 2021 | 177 | 0.150 |
Why?
|
| Algorithms | 2 | 2025 | 2014 | 0.150 |
Why?
|
| Receptors, Opioid | 1 | 2019 | 23 | 0.150 |
Why?
|
| Carcinogenesis | 1 | 2021 | 237 | 0.150 |
Why?
|
| Weight Loss | 1 | 2020 | 240 | 0.150 |
Why?
|
| Tobacco Smoking | 1 | 2019 | 31 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 518 | 0.150 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2018 | 43 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2023 | 47 | 0.140 |
Why?
|
| Smoking Cessation | 2 | 2019 | 272 | 0.140 |
Why?
|
| Homocysteine | 1 | 2018 | 30 | 0.140 |
Why?
|
| Adenosine | 1 | 2021 | 278 | 0.140 |
Why?
|
| Analysis of Variance | 2 | 2010 | 910 | 0.140 |
Why?
|
| Saliva | 1 | 2018 | 128 | 0.140 |
Why?
|
| Water Supply | 3 | 2014 | 66 | 0.130 |
Why?
|
| Agricultural Workers' Diseases | 1 | 2017 | 18 | 0.130 |
Why?
|
| Naltrexone | 1 | 2019 | 139 | 0.130 |
Why?
|
| Pesticides | 1 | 2017 | 30 | 0.130 |
Why?
|
| Biomarkers | 5 | 2023 | 1933 | 0.130 |
Why?
|
| Chromosomes, Human | 1 | 2017 | 67 | 0.130 |
Why?
|
| DNA Helicases | 1 | 2017 | 90 | 0.130 |
Why?
|
| Narcotic Antagonists | 1 | 2019 | 170 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 484 | 0.130 |
Why?
|
| Genotyping Techniques | 1 | 2017 | 71 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 647 | 0.130 |
Why?
|
| Occupational Exposure | 1 | 2017 | 89 | 0.120 |
Why?
|
| Mortality | 1 | 2017 | 154 | 0.120 |
Why?
|
| Adolescent | 8 | 2024 | 9896 | 0.120 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 3 | 2015 | 58 | 0.120 |
Why?
|
| Parents | 1 | 2018 | 307 | 0.120 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2015 | 76 | 0.120 |
Why?
|
| Blood Glucose | 1 | 1999 | 873 | 0.120 |
Why?
|
| Atherosclerosis | 1 | 2018 | 271 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 299 | 0.110 |
Why?
|
| Down-Regulation | 2 | 2021 | 527 | 0.110 |
Why?
|
| Water Wells | 3 | 2022 | 18 | 0.110 |
Why?
|
| Receptors, Progesterone | 1 | 2016 | 195 | 0.110 |
Why?
|
| Parity | 1 | 2015 | 97 | 0.110 |
Why?
|
| Asthma | 1 | 2023 | 1051 | 0.110 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2015 | 52 | 0.110 |
Why?
|
| Biological Assay | 1 | 2014 | 84 | 0.110 |
Why?
|
| Hypothyroidism | 1 | 2017 | 276 | 0.110 |
Why?
|
| Phosphofructokinase-1, Muscle Type | 1 | 2014 | 9 | 0.110 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 7232 | 0.110 |
Why?
|
| Up-Regulation | 2 | 2021 | 741 | 0.100 |
Why?
|
| Prednisolone | 1 | 1994 | 37 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 381 | 0.100 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 1994 | 23 | 0.100 |
Why?
|
| Odds Ratio | 4 | 2019 | 713 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 771 | 0.100 |
Why?
|
| alpha-Tocopherol | 1 | 2013 | 9 | 0.100 |
Why?
|
| Cluster Analysis | 2 | 2012 | 392 | 0.100 |
Why?
|
| Cyclophosphamide | 1 | 1994 | 313 | 0.100 |
Why?
|
| Age of Onset | 2 | 2017 | 344 | 0.100 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 71 | 0.100 |
Why?
|
| Feasibility Studies | 2 | 2019 | 819 | 0.090 |
Why?
|
| Methylation | 3 | 2019 | 295 | 0.090 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 321 | 0.090 |
Why?
|
| Frozen Sections | 1 | 2012 | 50 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2012 | 83 | 0.090 |
Why?
|
| Mosaicism | 1 | 2012 | 74 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2012 | 109 | 0.090 |
Why?
|
| Child | 4 | 2025 | 7626 | 0.090 |
Why?
|
| Chromosome Deletion | 1 | 2012 | 229 | 0.090 |
Why?
|
| Genes, Neoplasm | 1 | 2010 | 39 | 0.080 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 168 | 0.080 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 828 | 0.080 |
Why?
|
| Haplotypes | 2 | 2008 | 650 | 0.070 |
Why?
|
| Mutagens | 1 | 2009 | 30 | 0.070 |
Why?
|
| Placental Lactogen | 1 | 2008 | 12 | 0.070 |
Why?
|
| Gamma Rays | 1 | 2009 | 73 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2023 | 713 | 0.070 |
Why?
|
| Chorionic Gonadotropin | 1 | 2008 | 72 | 0.070 |
Why?
|
| Linear Models | 2 | 2025 | 438 | 0.070 |
Why?
|
| Healthy Volunteers | 2 | 2019 | 157 | 0.070 |
Why?
|
| Electronic Health Records | 2 | 2022 | 372 | 0.070 |
Why?
|
| DNA, Mitochondrial | 1 | 2009 | 197 | 0.070 |
Why?
|
| Protein Carbonylation | 1 | 2008 | 10 | 0.070 |
Why?
|
| Aromatase | 1 | 2007 | 12 | 0.070 |
Why?
|
| Lymphocytes | 2 | 2009 | 489 | 0.070 |
Why?
|
| Ultraviolet Rays | 1 | 2009 | 198 | 0.070 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2006 | 44 | 0.070 |
Why?
|
| Gene Amplification | 1 | 2008 | 143 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2012 | 592 | 0.070 |
Why?
|
| Genetic Markers | 2 | 2020 | 479 | 0.070 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2006 | 68 | 0.070 |
Why?
|
| Gene Expression | 2 | 2024 | 1322 | 0.060 |
Why?
|
| Placenta | 1 | 2008 | 191 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 3927 | 0.060 |
Why?
|
| Retrospective Studies | 1 | 2020 | 10286 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2025 | 3974 | 0.060 |
Why?
|
| Estrogens | 1 | 2006 | 203 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2008 | 938 | 0.060 |
Why?
|
| Mercury | 1 | 2025 | 12 | 0.060 |
Why?
|
| Nails | 1 | 2025 | 11 | 0.060 |
Why?
|
| Volatile Organic Compounds | 1 | 2024 | 4 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2017 | 599 | 0.060 |
Why?
|
| Silicones | 1 | 2024 | 21 | 0.060 |
Why?
|
| Wrist | 1 | 2024 | 29 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 1798 | 0.060 |
Why?
|
| United States | 3 | 2023 | 7767 | 0.060 |
Why?
|
| Multigene Family | 1 | 2025 | 213 | 0.060 |
Why?
|
| Nitrogen Dioxide | 1 | 2024 | 19 | 0.050 |
Why?
|
| Environmental Monitoring | 1 | 2024 | 89 | 0.050 |
Why?
|
| Enteroendocrine Cells | 1 | 2024 | 8 | 0.050 |
Why?
|
| Chromosome Mapping | 2 | 2022 | 1083 | 0.050 |
Why?
|
| Prognosis | 3 | 2018 | 4033 | 0.050 |
Why?
|
| Resistin | 1 | 2023 | 12 | 0.050 |
Why?
|
| Keratosis | 1 | 2003 | 21 | 0.050 |
Why?
|
| Ghrelin | 1 | 2023 | 29 | 0.050 |
Why?
|
| Troponin | 1 | 2023 | 28 | 0.050 |
Why?
|
| Diabetic Nephropathies | 1 | 2024 | 90 | 0.050 |
Why?
|
| Chromosomes, Human, Y | 1 | 2023 | 26 | 0.050 |
Why?
|
| Medically Uninsured | 1 | 2023 | 67 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 2463 | 0.050 |
Why?
|
| C-Peptide | 1 | 2023 | 186 | 0.050 |
Why?
|
| Leptin | 1 | 2023 | 102 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2008 | 813 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2025 | 404 | 0.050 |
Why?
|
| Genomic Instability | 1 | 2023 | 88 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 2 | 2 | 2016 | 85 | 0.050 |
Why?
|
| Adipocytes | 1 | 2024 | 172 | 0.050 |
Why?
|
| RNA | 1 | 2007 | 606 | 0.050 |
Why?
|
| Peripheral Arterial Disease | 1 | 2024 | 102 | 0.050 |
Why?
|
| Metabolomics | 1 | 2023 | 98 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2019 | 703 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 281 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2023 | 182 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2023 | 198 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 204 | 0.040 |
Why?
|
| Islam | 1 | 2022 | 34 | 0.040 |
Why?
|
| Nedd4 Ubiquitin Protein Ligases | 1 | 2021 | 14 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2021 | 37 | 0.040 |
Why?
|
| Sequestosome-1 Protein | 1 | 2021 | 23 | 0.040 |
Why?
|
| Vacuoles | 1 | 2021 | 48 | 0.040 |
Why?
|
| Protein Stability | 1 | 2021 | 106 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2013 | 1791 | 0.040 |
Why?
|
| Data Collection | 1 | 2022 | 381 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2024 | 482 | 0.040 |
Why?
|
| Epidermis | 1 | 2021 | 104 | 0.040 |
Why?
|
| Chromatin | 1 | 2024 | 446 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2022 | 213 | 0.040 |
Why?
|
| RNA Stability | 1 | 2021 | 97 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2024 | 559 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2003 | 484 | 0.040 |
Why?
|
| Medicaid | 1 | 2023 | 260 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2024 | 781 | 0.040 |
Why?
|
| Lysosomes | 1 | 2021 | 124 | 0.040 |
Why?
|
| Keratinocytes | 1 | 2021 | 146 | 0.040 |
Why?
|
| Immunochemistry | 1 | 2019 | 18 | 0.040 |
Why?
|
| Waist-Hip Ratio | 1 | 2019 | 21 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2019 | 24 | 0.040 |
Why?
|
| Multifunctional Enzymes | 1 | 2019 | 7 | 0.040 |
Why?
|
| Clostridiales | 1 | 2019 | 18 | 0.040 |
Why?
|
| Thinness | 1 | 2019 | 45 | 0.040 |
Why?
|
| Social Class | 1 | 1999 | 145 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2024 | 394 | 0.040 |
Why?
|
| Cetylpyridinium | 1 | 2018 | 2 | 0.040 |
Why?
|
| Folic Acid | 1 | 2019 | 64 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 296 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2021 | 706 | 0.040 |
Why?
|
| DNA Barcoding, Taxonomic | 1 | 2018 | 14 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2022 | 391 | 0.040 |
Why?
|
| Peroxidase | 2 | 2012 | 54 | 0.040 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2018 | 82 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2021 | 466 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2018 | 214 | 0.030 |
Why?
|
| Body Weight | 1 | 2019 | 460 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2021 | 469 | 0.030 |
Why?
|
| Iowa | 1 | 2017 | 35 | 0.030 |
Why?
|
| North Carolina | 1 | 2017 | 56 | 0.030 |
Why?
|
| Freezing | 1 | 2017 | 32 | 0.030 |
Why?
|
| Base Sequence | 1 | 2021 | 2344 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2018 | 92 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2019 | 302 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2019 | 339 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 983 | 0.030 |
Why?
|
| Longevity | 1 | 2017 | 60 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1999 | 501 | 0.030 |
Why?
|
| Cyclophilins | 1 | 2016 | 8 | 0.030 |
Why?
|
| tRNA Methyltransferases | 1 | 2016 | 14 | 0.030 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2016 | 50 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2017 | 281 | 0.030 |
Why?
|
| Menopause | 1 | 2016 | 90 | 0.030 |
Why?
|
| Thyrotropin | 1 | 2017 | 311 | 0.030 |
Why?
|
| Cytochrome P-450 CYP1B1 | 2 | 2006 | 10 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2015 | 60 | 0.030 |
Why?
|
| Triiodothyronine | 1 | 2017 | 362 | 0.030 |
Why?
|
| Inositol Polyphosphate 5-Phosphatases | 1 | 2015 | 2 | 0.030 |
Why?
|
| Heterozygote | 1 | 2016 | 382 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2015 | 98 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2092 | 0.030 |
Why?
|
| Thyroxine | 1 | 2017 | 388 | 0.030 |
Why?
|
| Asia | 1 | 2014 | 105 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2016 | 215 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2014 | 93 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2015 | 2480 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2860 | 0.030 |
Why?
|
| Proteinuria | 1 | 1994 | 70 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 1268 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1546 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2015 | 477 | 0.030 |
Why?
|
| Animals | 3 | 2021 | 28945 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2016 | 594 | 0.020 |
Why?
|
| E-Selectin | 1 | 2012 | 31 | 0.020 |
Why?
|
| Genes, Homeobox | 1 | 2012 | 84 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2012 | 46 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 86 | 0.020 |
Why?
|
| Genomics | 1 | 2018 | 855 | 0.020 |
Why?
|
| Survival Rate | 1 | 2016 | 1986 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2004 | 930 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 1994 | 1010 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 1158 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2012 | 437 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 1994 | 432 | 0.020 |
Why?
|
| Asbestos | 1 | 2009 | 22 | 0.020 |
Why?
|
| Cricetulus | 1 | 2009 | 132 | 0.020 |
Why?
|
| CHO Cells | 1 | 2009 | 196 | 0.020 |
Why?
|
| Kidney | 1 | 1994 | 1156 | 0.020 |
Why?
|
| Carcinogens | 1 | 2009 | 106 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2008 | 42 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2008 | 79 | 0.020 |
Why?
|
| Cricetinae | 1 | 2009 | 544 | 0.020 |
Why?
|
| Drinking | 1 | 2008 | 35 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2008 | 102 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2007 | 17 | 0.020 |
Why?
|
| Premenopause | 1 | 2007 | 63 | 0.020 |
Why?
|
| Methylenetetrahydrofolate Dehydrogenase (NADP) | 1 | 2007 | 5 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2008 | 133 | 0.020 |
Why?
|
| Mice | 1 | 2021 | 12562 | 0.020 |
Why?
|
| DNA Damage | 1 | 2009 | 392 | 0.020 |
Why?
|
| Hydroxyestrones | 1 | 2006 | 4 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 411 | 0.020 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2006 | 18 | 0.020 |
Why?
|
| Population Groups | 1 | 2006 | 42 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 5585 | 0.020 |
Why?
|
| Codon | 1 | 2006 | 120 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 2007 | 148 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 517 | 0.020 |
Why?
|
| Melanosis | 1 | 2005 | 6 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 9173 | 0.010 |
Why?
|
| Estradiol | 1 | 2006 | 256 | 0.010 |
Why?
|
| Stroke | 1 | 2015 | 1087 | 0.010 |
Why?
|
| Cell Line | 1 | 2009 | 2533 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2005 | 688 | 0.010 |
Why?
|
| Catalase | 1 | 2003 | 49 | 0.010 |
Why?
|
| Pedigree | 1 | 2004 | 982 | 0.010 |
Why?
|
| Pregnancy | 1 | 2008 | 3240 | 0.010 |
Why?
|